Cognitive Decline in Alzheimer's Not Helped by Vitamin B Supplements

A new study from University of California, San Diego School of Medicine has found that high doses of vitamin B fail to slow down cognitive decline in Alzheimer's patients.

In a research conducted to decide if reduction of an amino acid, homocysteine, through the increased intake of Vitamin B would slow down the progression of Alzheimer’s, scientists at the University of California, San Diego School of Medicine found that it is not so. According to them, high doses of vitamin B fails to slow down cognitive decline in Alzheimer's patients.

Homocysteine is known to be involved in neurological disease, including Alzheimer's, and B vitamins affected its metabolism. Therefore, it was thought that B vitamin supplements might offer a new therapeutic approach in treating Alzheimer' disease.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

"Prior studies using B vitamin supplementation to reduce homocysteine levels in patients with Alzheimer's weren't large enough, or of long enough duration to effectively assess their impact on cognitive decline," said Dr Paul S. Aisen, professor of neurosciences at the University of California, San Diego School of Medicine.

"This study of several hundred individuals over the course of 18 months showed no impact on cognition, although it resulted in lower levels of homocysteine in these patients," he added.

During the study, the 409 participants with mild or moderate Alzheimer's received folic acid and vitamins B6 and B12 for 18 months.

World Alzheimer's Day
World Alzheimer’s Day on September 21st, 2008, embodying the theme ‘No time to lose’ recognizes the role of caregivers as the backbone of care, support and management of Alzheimer’s disease.

They were randomly assigned to two groups of unequal size; to increase enrolment, 60 percent were treated with high-dose supplements and the remaining 40 percent treated with identical dosages of placebo.

A total of 340 participants (202 in active treatment group and 138 in placebo group) completed the trial while taking study medication.

Estrogen ? May Be a Good Therapy for Women Before They Turn 65
It might be a double blessing for those women who are on estrogen therapy before the age of 65.

The cognitive abilities were measured via testing with the Alzheimer Disease Assessment Scale (ADAS-cog).

The researchers found that the ADAS-cog score did not differ significantly between treatment groups, but that symptoms of depression were more common in the high-dose supplement group.

Risk Factors for Alzheimer's Disease Depend on Gender
French researchers have found that the risk factors for developing Alzheimer's disease are dependent on the gender of a person.

"Our study does not support the treatment of individuals with mild to moderate Alzheimer's disease and normal vitamin levels with B vitamin supplements," said the authors.

The study is published in Journal of the American Medical Association (JAMA).

Source-ANI
TAN/M